HONG KONG, May 15, 2026 - (ACN Newswire) - Everest Medicines (HKEX: 1952.HK) announced that on 14 May 2026, based on strong confidence in the company’s future prospects and long-term development, Mr. Wei Fu, a non-executive Director, the honorary chairman of the Board and a substantial shareholder of the company, purchased 660,000 ordinary shares of the company on the open-market for a total consideration of approximately HK$20.7 million, representing an average price of approximately HK$31.25 per Share. Mr. Wei Fu pointed out that he does not rule out the possibility of further increasing his shareholdings in the company when appropriate.

This marks Mr. Wei Fu’s second share purchase in Everest Medicines in 2026. Previously, on March 27, he acquired 860,000 shares of Everest Medicines at an average price of approximately HK$38.12 per share, for a total consideration of approximately HK$32.7 million.

Mr. Wei Fu’s consecutive share purchases within the year reflect his firm confidence in both Everest Medicines' strategic direction and operational achievements. At the end of 2025, Everest Medicines unveiled its 2030 strategy, which clearly adopts a dual-engine approach driven by both business development collaborations and in-house R&D. By 2030, the company aims to achieve revenue exceeding RMB15 billion and expand its commercialized product portfolio to more than 20 products, while continuing to focus on high-growth therapeutic areas including nephrology, cardiovascular and metabolic diseases. In December 2025, the management team and substantial shareholders collectively increased their shareholdings in the market, signaling long-term confidence in the company’s development.

On the operational front, Everest Medicines reported total revenue of RMB1.707 billion for the full year of 2025, representing a year-over-year increase of 142%. The company also achieved annual profitability for the first time on a non-IFRS basis, recording a profit of RMB187 million, while operating cash flow turned positive in the fourth quarter. Sales revenue of NEFECON® reached RMB1.443 billion, representing growth of more than 300% year-over-year, making it the first non-oncology innovative drug in China to exceed RMB1 billion in annual sales in its first year of inclusion in the National Reimbursement Drug List (NRDL). Meanwhile, XERAVA® achieved sales revenue of RMB262 million, with in-hospital sales increasing by 44% year-over-year. These results further validate the company’s strengthening commercialization capabilities and continued execution momentum.

The management team’s collective shareholding increases and Mr. Fu’s consecutive share purchases in 2026 demonstrated strong confidence in the Company’s long-term prospects. Supported by strong operational execution and strategic implementation, Everest Medicines’ medium- to long-term growth trajectory is becoming increasingly clear.

Highlights:

• WellCare Today brings established RPM, RTM and CCM infrastructure with wearable technology integrations and connected monitoring solutions
• Combination expected to integrate Wellgistics Health recently announced MSO initiative with Kare Clinicals and its network of 6,500+ independent pharmacies
• Proposed platform designed to enhance patient engagement, medication adherence, remote monitoring and longitudinal care coordination
• Proposed transaction valued at approximately $15 million
• Strategic initiative intended to create additional clinical revenue opportunities for participating pharmacies and providers

TAMPA, FLA., May 15, 2026 - (ACN Newswire) - Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics" or the "Company"), a leading healthcare technology and pharmaceutical distribution company, today announced that it has executed a non-binding letter of intent ("LOI") to acquire WellCare Today. The proposed transaction structure includes a structured cash payment of $3 million, with the balance to be satisfied through a performance-based earnout issued in preferred stock.

WellCare Today is a healthcare technology and remote monitoring company focused on chronic care management ("CCM"), remote patient monitoring ("RPM"), and remote therapeutic monitoring ("RTM") programs. The company delivers HealthAssist®, an advanced remote health monitoring platform embedded within standalone Samsung Galaxy Watch devices as part of its broader Health Monitoring & Emergency Support Ecosystem. The platform enables passive, continuous monitoring of key health metrics including heart rate, blood oxygen levels, temperature, sleep patterns, activity tracking, and self-reported medication adherence through Medicare-reimbursable RPM and RTM programs. No assurance can be given that any particular patient, provider, pharmacy, service, device or workflow will qualify for reimbursement.

Under the proposed transaction structure, Wellgistics Health intends to integrate WellCare Today's HealthAssist® platform and RPM, RTM and CCM capabilities with the Company's recently announced MSO pilot collaboration involving Kare Clinicals, a division of Kare PharmTech, LLC, as well as its network of more than 6,500 independent pharmacies. The combined infrastructure is intended to support scalable patient engagement, medication adherence initiatives, longitudinal monitoring programs, chronic disease management, and enhanced care coordination workflows across provider and pharmacy channels utilizing connected wearable technologies and remote monitoring infrastructure.

The proposed transaction is also expected to create opportunities for participating pharmacies within the Wellgistics Pharmacy Network to engage in clinical service programs associated with RPM, RTM and CCM initiatives, while enabling providers to access scalable care coordination, monitoring, and reimbursement infrastructure. The companies believe the proposed collaboration may establish a more connected healthcare ecosystem aligning patients, pharmacies, providers, wearable technologies, and longitudinal care coordination services through technology-enabled engagement and remote monitoring platforms.

The LOI is non-binding, and completion of the proposed transaction remains subject to customary due diligence, negotiation and execution of definitive agreements, board approvals, financing considerations, and other customary closing conditions. There can be no assurance that a definitive agreement will be executed or that the proposed transaction will be completed as currently contemplated, or at all.

About Wellgistics Health, Inc.

Wellgistics Health (NASDAQ:WGRX) is a health information technology leader integrating its proprietary pharmacy dispensing optimization artificial intelligence platform EinsteinRx™ into its blockchain-enabled smart contracts platform PharmacyChain™ to optimize the prescription drug dispensing journey. Its integrated platform connects more than 6,500 pharmacies and 200+ manufacturers, offering wholesale distribution, digital prescription routing, direct-to-patient delivery, and AI-powered hub services such as eligibility verification, onboarding, adherence support, prior authorization, and cash-pay fulfillment designed to improve patient access and transparency across the prescription ecosystem.

About WellCare Today, LLC

WellCare Today is a healthcare technology company delivering HealthAssist®, an advanced remote health monitoring platform embedded within standalone Samsung Galaxy Watch devices as part of its comprehensive Health Monitoring & Emergency Support Ecosystem. HealthAssist® enables passive, continuous monitoring of key health metrics including hourly heart rate, hourly blood oxygen levels, temperature, daily steps, sleep patterns, and self-reported medication adherence. Integrated with Remote Therapeutic Monitoring (RTM) and Remote Patient Monitoring (RPM) programs reimbursable by Medicare, HealthAssist® delivers an affordable, scalable solution designed to support seniors and individuals managing chronic health conditions.

All RPM, RTM, CCM and related care-coordination services are expected to be furnished, supervised, documented and billed by appropriately licensed providers and participating entities in accordance with applicable federal and state healthcare laws, Medicare and payor requirements, fraud and abuse laws, privacy and data-security requirements, and professional practice rules. The Company does not provide medical advice through this press release, and participation in any program will be subject to applicable clinical, contractual, regulatory and reimbursement requirements.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other applicable federal securities laws. Forward-looking statements include, without limitation, statements regarding the proposed acquisition of WellCare Today, LLC; the anticipated structure, valuation, consideration, preferred-stock terms and potential timing of any transaction; the Company's ability to complete due diligence, negotiate and enter into definitive agreements, obtain board approvals, secure financing, satisfy closing conditions and complete the proposed transaction; the potential integration of WellCare Today's platform, technology, personnel, programs and workflows with the Company's MSO, pharmacy network, provider and healthcare technology initiatives; the potential use of HealthAssist® and connected wearable technologies in RPM, RTM, CCM, medication adherence, patient engagement and care-coordination programs; the potential participation of pharmacies, providers, patients and payors; the potential availability of reimbursement for RPM, RTM, CCM or related services; the potential creation of revenue opportunities; and the Company's growth strategy, business plans and future performance.

Forward-looking statements may be identified by words such as "may," "could," "would," "should," "expect," "anticipate," "believe," "intend," "plan," "project," "estimate," "potential," "opportunity," "target," "forecast," "continue," "will" and similar expressions. These statements are based on current expectations, assumptions and estimates and are subject to risks and uncertainties, many of which are beyond the Company's control. Important factors that could cause actual results to differ materially include, but are not limited to: the risk that the parties do not enter into definitive agreements; the risk that the letter of intent is terminated or does not result in a completed transaction; the risk that the proposed valuation, consideration, preferred-stock terms or other transaction terms change materially; the risk that required financing, board approvals, third-party approvals or regulatory approvals are not obtained on acceptable terms or at all; the risk that Nasdaq shareholder approval or other Nasdaq requirements may apply depending on the final transaction terms; the risk that acquired technologies, programs or operations are not successfully integrated; the risk that anticipated benefits, synergies, provider adoption, pharmacy participation, patient engagement, reimbursement or revenue opportunities are not realized; risks associated with healthcare regulation, Medicare and payor requirements, fraud and abuse laws, privacy and data-security requirements, professional practice rules, device performance, third-party technology dependencies and changes in reimbursement policy; and other risks and uncertainties described in the Company's filings with the U.S. Securities and Exchange Commission.

Forward-looking statements speak only as of the date they are made, and the Company undertakes no obligation to update or revise any forward-looking statements, except as required by applicable law.

Wellgistics Media & Investor Contact
Media: media@wellgisticshealth.com
Investor Relations: IR@wellgisticshealth.com

SOURCE: Wellgistics Health, Inc.

Highlights:

• According to third-party industry reports, the U.S. RPM market is currently $14 Billion alone and expected to reach approximately $29 Billion by 2030, representing a 12.6% CAGR, as healthcare providers continue shifting toward value-based and home-based care models¹
• Pilot initiative launched across multiple provider offices focused on chronic care management (CCM) and remote patient monitoring (RPM) through it's MSO infrastructure
• Approximately 1,500+ claims generated to date through the pilot infrastructure with expansion roadmap targeting additional providers
• Wellgistics Pharmacy Network of 6,500+ independent pharmacies positioned to support patient engagement and care coordination initiatives
• Participating pharmacists expected to gain access to new clinical service revenue opportunities

TAMPA, FLA., May 13, 2026 - (ACN Newswire) - Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics" or the "Company"), a leading healthcare technology and pharmaceutical distribution company, today announced a pilot collaboration with Kare PharmTech and Kare Clinicals integrating its MSO infrastructure to support chronic care management ("CCM") and remote patient monitoring ("RPM") services across participating provider offices. According to third-party industry reports, the U.S. RPM market is currently $14 Billion and expected to reach approximately $29 Billion by 2030, representing a 12.6% CAGR, as healthcare providers continue shifting toward value-based and home-based care models.¹

The pilot program currently includes multiple provider offices, with Kare Clinicals MSO serving as the billing provider on behalf of participating offices and rendering providers. The initiative is designed to support patient engagement, care coordination, and longitudinal monitoring programs through scalable operational and technology-enabled workflows. All CCM and RPM services are expected to be furnished and billed by appropriately licensed providers and participating entities in accordance with applicable federal and state healthcare laws, reimbursement requirements, and payor program rules.

The companies stated that the pilot infrastructure has already generated 1,500+ claims and is intended to serve as the foundation for broader expansion efforts targeting approximately additional providers over time. As part of the collaboration, Wellgistics Health intends to leverage its network of more than 6,500 independent pharmacies to help identify and support eligible patients who may benefit from CCM and RPM services. Participating pharmacies within the Wellgistics Pharmacy Network may also have opportunities to participate in clinical engagement initiatives associated with the program.

Prashant Patel, President and CEO of Wellgistics Health, Inc., stated, "We believe the convergence of pharmacy engagement, provider connectivity, and technology-enabled care coordination represents a significant opportunity to improve patient outcomes while creating new economic opportunities for independent pharmacies. Through this pilot collaboration with Kare PharmTech, we are establishing infrastructure designed to support scalable patient engagement models across chronic care management and remote patient monitoring programs."

Mital Panera, Founder and Chief Executive Officer of Kare PharmTech, added, "Our focus has been on building an operationally efficient MSO platform capable of supporting providers with care coordination and reimbursement workflows. By collaborating with Wellgistics Health and its pharmacy network, we believe we can further expand patient participation, improve continuity of care, and create a scalable framework for future provider growth."

The companies noted that the pilot program remains subject to ongoing operational development, provider participation, and regulatory compliance considerations as expansion efforts continue.

About Wellgistics Health, Inc.

Wellgistics Health (NASDAQ:WGRX) is a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence platform EinsteinRx™ into its patented blockchain-enabled smart contracts platform PharmacyChain™ to optimize the prescription drug dispensing journey. Its integrated platform connects 6,500+ pharmacies (the "Wellgistics Pharmacy Network") and 200+ manufacturers, offering wholesale distribution, digital prescription routing, direct-to-patient delivery, and AI-powered hub services such as eligibility, adherence, onboarding, prior authorization, and cash-pay fulfillment as needed to optimize patient access. Wellgistics provides end-to-end solutions designed to restore access, transparency, and trust in the U.S. prescription drug market for independent pharmacies.

About Kare PharmTech, LLC

Kare Clinicals is part of the larger ecosystem of companies owned by Kare PharmTech, LLC, a company controlled by Dr. Kiran Patel. Dr. Patel founded Medicaid provider WellCare in 1992 and sold it in 2002 for $200 million. In 2007, Dr. Patel founded America's 1st Choice Holdings and acquired Freedom Health and Optimum Holdings. In 2017, he sold America's 1st Choice Holdings to Anthem, Inc. Dr. Patel is a noted philanthropist and was named Floridian of the Year by Florida Trend Magazine.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding the Company's expectations, beliefs, plans, objectives, intentions, strategies, future events, or performance, including statements regarding the potential benefits, scalability, expansion, commercialization, provider participation, reimbursement opportunities, patient engagement initiatives, operational capabilities, and future development of the pilot collaboration with Kare PharmTech and Kare Clinicals, as well as the anticipated role of the Wellgistics Pharmacy Network in supporting CCM and RPM initiatives. Words such as "anticipate," "believe," "could," "expect," "intend," "may," "plan," "potential," "project," "seek," "should," "will," and similar expressions are intended to identify forward-looking statements.

These forward-looking statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Such risks and uncertainties include, without limitation, risks relating to provider adoption and participation, reimbursement outcomes, patient engagement levels, operational execution, scalability of the pilot program, regulatory and healthcare compliance considerations, changes in applicable laws or reimbursement policies, market acceptance of the Company's services, competitive factors, and the Company's ability to develop and maintain strategic relationships and successfully implement its business strategy.

The pilot collaboration described in this press release is exploratory in nature, and there can be no assurance that the initiative will result in expanded commercial relationships, material revenue opportunities, or long-term operational success.

Additional information regarding these and other risks can be found in the Company's filings with the U.S. Securities and Exchange Commission, including the risk factors contained therein. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

Wellgistics Media & Investor Contact
Media: media@wellgisticshealth.com
Investor Relations: IR@wellgisticshealth.com

[1] MarketsandMarkets - U.S. Remote Patient Monitoring Market Report

SOURCE: Wellgistics Health, Inc.

HONG KONG, May 13, 2026 - (ACN Newswire) - The sixth Asia Summit on Global Health (ASGH), jointly organised by the Government of the Hong Kong Special Administrative Region and the Hong Kong Trade Development Council (HKTDC), and the 17th Hong Kong International Medical and Healthcare Fair (Medical Fair), organised by the HKTDC and co-organised by the Hong Kong MedTech Association, have concluded successfully. As one of the two flagship events of International Healthcare Week, the ASGH gathered some 3,000 participants from 43 countries and regions and arranged over 400 one‑on‑one deal-making meetings, while also facilitating the signing of multiple cooperation agreements, with a strong focus on the application of artificial intelligence. Meanwhile, the Medical Fair welcomed some 13,000 buyers from 61 countries and regions for sourcing and networking. More than 670 business matching meetings were arranged during the fair, supporting buyers and exhibitors in identifying potential partners and advancing concrete business discussions. Together, the two flagship events facilitated over 1,000 high-quality collaborations and connections, fully demonstrating the synergy between medical technology, investment and industry applications.

Over 90 global leaders share insight into healthcare innovation development and AI applications

The sixth ASGH, a two-day event jointly organised by the Government of the Hong Kong Special Administrative Region and the HKTDC, has concluded under the theme Fuelling Healthcare Breakthroughs, focusing on public health, frontier healthcare technologies, AI breakthroughs, healthcare investment and the silver health. The ASGH brought together over 90 international healthcare officials, scientific pioneers, Nobel laureate, investors and corporate leaders to share insight and explore pathways to accelerate innovation across the global healthcare ecosystem.

At Plenary Session I – Strengthening Pandemic Preparedness through Global Collaboration. Prof Ibrahim Abubakar, Vice‑Provost (Health) and Professor of Infectious Disease Epidemiology, University College London, said: “Research platforms need to be developed long in advance of pandemics, and we must invest in infectious disease infrastructure, and beyond, whether it’s in AI technology or in  disease management.”

Plenary Session II – Fuelling Healthcare Breakthroughs centred on the commercialisation of medical research, biomedical innovation and healthcare investment opportunities. Jonathan Symonds, Chair of GSK, said: “All developed countries are now facing ageing, low birth rates and an increasing impact of chronic disease. So, it's no longer just a health system problem, but it's now an economic problem.”

During the Dialogue with Global Pioneer in Health session, Prof Michael Levitt, 2013 Nobel Laureate in Chemistry and Robert W and Vivian K Cahill Professor of Cancer Research at the Stanford University School of Medicine, said that Hong Kong’s healthcare system possesses unique advantages and high-quality statistical data, making it potentially more valuable for research than the US and other countries or regions, in  areas such as longevity.

The ASGH featured multiple thematic sessions spotlighting the application of AI in healthcare. Sustaining the momentum of the “Intelligence at Scale: How AI is Powering Real-World Healthcare Revolution” session on the first day, another thematic session on the second day, “Transforming Healthcare through Digital Health & AI Innovations”, explored how digital technologies and artificial intelligence are reshaping healthcare systems. Natasha Chhatrapati, Senior Director, Business Transformation Lead for International, Pfizer Inc., said: “AI is compressing timelines across the entire healthcare journey, from drug development and clinical research to how we engage with physicians and how patients consume care.”

The session “The Next Frontier in China’s Healthcare Industry” examined strategies to advance the Chinese Mainland healthcare sector. Dr James Xue, Founder, Chairman and CEO of CANbridge Pharmaceuticals Inc, said: “China has an edge because of the population. A bigger population base will allow companies to build better drug candidates.”

With silver health emerging as a major global focus, the Silver Health Chapter included the session “Unlocking Growth in Silver Health: From Precision Medicine to Smart Ageing Innovations”, which brought together leading experts to discuss challenges and opportunities arising from population ageing. Dr Alex Mihailidis, Associate Vice‑President, International Partnerships and Professor at the University of Toronto and Scientific Director at AGE‑WELL, provided in‑depth insight into breakthroughs in prevention and treatment of age‑related diseases, offering guidance for the development of the silver health economy and smart ageing solutions. He said: “For a technology to be successful with older people, it’s not just the technology, but also the service delivery model, as well as the practice and policy.”

The newly introduced session “CSO Insights: Catalysing Scientific Breakthroughs and Investments for Future Health” featured discussions on research strategy and the acceleration of scientific discoveries into practical applications. Dr Li Xiang, Senior Vice President, Co-President and Chief Scientific Officer, Innovative Medicines Division, Fosun Pharma, said: “In our business, it is very important to begin with the end in mind. When you set out to do your discovery program, you must already know what the unmet needs are and how difficult the clinical trials will be.”

Over 400 deal‑making sessions drive investment and business matching

Beyond thought leadership, the ASGH continued to serve as an effective platform for deal‑making and investment matching. Dedicated deal-making at the ASGH facilitated one‑to‑one meetings to promote tangible collaboration.

During the ASGH, over 400 business and investment matching meetings were arranged, attracting investment institutions and healthcare enterprises from Europe, the US, Asia and the Guangdong‑Hong Kong‑Macao Greater Bay Area to explore opportunities in investment, technology deployment and market expansion.

Colin Tan, Director of Operations at TusPark Holdings, an investor from the UK, said: “This year, I brought around 15 UK healthcare and life sciences companies to exhibit at the UK Pavilion. The ASGH has been an excellent platform to forge such connections. We are now facilitating a significant partnership in cancer research between a leading UK organisation and a Hong Kong counterpart.”

ASGH also featured the ASGH Business Hub and the InnoHealth Showcase, bringing together some 180 healthcare innovation companies from 12 countries and regions to present cutting‑edge solutions across biotechnology, digital health and medical technologies.

Strategic Partner of this year’s Summit, Shanghai Industrial Investment (Holdings) led multiple subsidiaries in exhibiting at the ASGH. Gu Feng, Chief Finance and Investment Officer, said that the ASGH fully showcased Hong Kong’s international competitiveness: “Chinese companies expanding overseas will come to Hong Kong, and foreign companies seeking to procure will do the same. Here we can not only acquire resources, but also connect and match resources, talent, capital, and other key elements.”

AQ Biotech from Finland, exhibiting at ASGH for the first time, said that their objective was to explore the Asian market. They view Hong Kong as a vital hub that adds internationally recognised credibility, connectivity and commercial acumen, helping them take their work global.

Dr Iman Manavitehrani, Founder and Director of SDIP Innovations, the Australian exhibitor returning for the second year, said: “Last year’s visit led directly to an IGNITE grant from HSITP, and we are now part of the first Australian cohort based here. With Hong Kong as our gateway to the GBA and Chinese Mainland, I am confident the connections made at the ASGH will lead to further collaboration and partnership.”

Third-time exhibitor, Prof Leung Kam-tong, Founder and CEO of local healthcare startup Homing Pharmaceuticals, said: “We’ve already reconnected with three investors here for in-depth discussions on our fundraising strategy, taking our navigated CAR-T therapy to first-in-human clinical trials. Sessions outside my field sparked new ideas around refining the therapy and exploring new directions. I also met professors from Australia and Singapore, and look forward to exploring international R&D collaborations as we bring this therapy worldwide.”

Building bridges for “go global” and other cross‑border healthcare collaborations

Building on its track record of facilitating collaboration, the ASGH enabled the signing of 10 Memoranda of Understanding (MoUs), such as those between the HKSH Medical Group and Siemens Healthineers, as well as Australian AI-powered clinical documentation platform startup Heidi Health, which signed separate agreements with local medical group EC Healthcare and Hong Kong Metropolitan University. These collaborations will drive deeper cooperation, including AI‑enabled healthcare applications and clinical research, further reinforced the ASGH’s role as a bridge connecting the Chinese Mainland and international healthcare ecosystems. Notably, HKSH Medical Group and Siemens Healthineers signed an agreement, formally establishing HKSH as Siemens Healthineers’ first Photon Counting Computed Tomography Simulation (PCCT-Sim) Reference Site in Asia.

On the second day, the GoGlobal CONNECT series: Hong Kong as a Superconnector to Empower Global Expansion of Pharmaceutical Enterprises workshop brought together experts in regulation, clinical trials, IP protection and distribution to share practical insight on international expansion. Prof Bernard Cheung, Chief Executive Officer, Greater Bay Area International Clinical Trial Institute, said: “Public hospitals in Hong Kong have very good electronic medical records that go back 30 years. It’s a unique asset that benefits not just people in Hong Kong but the world, as it allows us to study the long-term progression of diseases.”

The ASGH also featured the “GoGlobal Connect” and the Business of Healthcare Advisory Zone, enabling healthcare enterprises to connect with service providers and receive practical support for developing “go global” strategies. Xiang Jun, Chairman of 365 Intelligence (Beijing) Medical Technology Co., Ltd, said that the ASGH helped them gain a deeper understanding of Hong Kong’s professional services and of HKTDC’s “GoGlobal Connect” initiative. The company is particularly interested in Hong Kong’s research data and service resources, and plans to establish research operations in Hong Kong in the long term. Mark Xu, Regional Director of Sales and Marketing, Guangzhou Wondfo Biotech Co, Ltd, also successfully connected with service providers, including DKSH and the Greater Bay Area International Clinical Trial Institute, through this workshop. They engaged in in-depth discussions on potential collaboration opportunities for “going global”.

During the summit, the HKTDC signed a Memorandum of Understanding with the Hong Kong Singapore Business Association (HSBA), supporting Mainland enterprises’ “going global” via Hong Kong to target the Singapore and ASEAN markets. Prime Minister and Minister for Finance of Singapore Lawrence Wong visited Hong Kong in March this year, during which both governments agreed to deepen cooperation. The HSBA and the HKTDC, together with professional service providers, plan to strengthen trade and economic ties between the two cities. By leveraging their respective strengths and promoting complementary cooperation, they aim to drive business development, assist Chinese Mainland enterprises in expanding regionally and internationally, and enhance tripartite collaboration among Singapore, Hong Kong, and the Chinese Mainland.

The Medical Fair brings together global industry players to foster diverse collaborations, strengthening Hong Kong’s status as a global healthcare hub

The Medical Fair was being held concurrently. Organised by the HKTDC and co-organised by the Hong Kong MedTech Association, the Medical Fair adopted the theme Innovations Boosting Smart Health Experience. Focusing on three key areas: MedTech, GeronTech, and Preventive Healthcare, the event provided a high-efficiency trade and matchmaking platform for global R&D institutions, manufacturers, and medical professionals to showcase the latest industry trends. The number of exhibitors featuring smart ageing products and green solutions doubled this year, with many showcasing innovative solutions integrating AI and robotics to meet evolving market demands.

The Medical Fair featured some 300 exhibitors from 10 countries and regions, including Hong Kong, Chinese Mainland, Macao, Taiwan, Australia, Canada, Korea, New Zealand, United States and Vietnam. The Fair featured seven major zones, including Startup Zone, Hospital Equipment and Digital Health, Biotech and Lab Diagnostics, Laboratory Technologies and Healthcare Services, Medical Supplies, and the World of Health and Wellness, showcasing the latest medical technologies and innovative solutions. Pavilions from leading local universities, the Hong Kong Science and Technology Parks, and the Hong Kong MedTech Association underscored a multi-sector commitment to fostering collaborative innovation across government, industry, academia, research, and investment sectors.

Exhibitors acknowledged that AI has become a core driver of healthcare services, while the Medical Fair serves as a one-stop platform that brings together a complete healthcare ecosystem, successfully integrating AI, robotics technology and a wide range of smart medical devices. Wong Cheung Hang, Sales and Marketing Manager of Health Care & Co, a medical and rehabilitation equipment company in Hong Kong, said, “Buyers showed particular interest in our AI management systems, AI-assisted robots and various smart healthcare applications. With healthcare providers increasingly adopting smart health solutions, the market outlook is promising. We expect this fair to drive at least 20% business growth compared with last edition and enable us to promote smart rehabilitation technologies.”  Many overseas exhibitors succeeded in securing business matching opportunities at the fair. Peter Li, Chief Executive Officer of first-time exhibitor GenomeMe Lab Inc from Canada, said, “We connected with buyers from Hong Kong, Thailand and India, and identified potential local partners in the healthcare and hospital sectors. This will help us explore entry into hospital channels, establish distribution networks, and lay the groundwork for future expansion into Southeast Asia, Australia and Korea.”

The Medical Fair has facilitated numerous cross-regional collaborations, serving as a key platform for industry exchange and business matching. Dresio Limited, participating in the Fair for the third time under the banner of Hong Kong Science and Technology Parks, showcased its contactless physiotherapy assessment system Accudex, drawing strong interest from buyers across Hong Kong, Chinese Mainland, Singapore and the Philippines. Curtis Wong, Chief Operating Officer and Head of Research and Development of the company, said, “This year’s fair outperformed previous editions in footfall, business exchanges and partnership discussions. We have engaged with a large number of high-quality buyers from hospitals, rehabilitation centres and the insurance sector.” The company met with a Filipino buyer on the first day of the exhibition and subsequently signed a Memorandum of Understanding (MOU) on the third day, expanding its software into Southeast Asia, with the contract value expected to exceed HK$1 million.

The Medical Fair was held concurrently with the ASGH and the Hospital Authority (HA) Convention, bringing together key industry stakeholders and generating strong synergy. Exhibitors were able to seize the opportunity to meet with numerous representatives from the Hospital Authority and major healthcare institutions, fostering meaningful exchanges and collaboration. Among them, first-time exhibitor PalmX Technology Limited showcased its palm vein biometric technology at the Startup Zone. Jeffrey Lo, Vice President of the company, was impressed by the Fair’s response, which exceeded his expectations. He added that within the first two days, they received over 20 enquiries from hospitals and healthcare institutions, including representatives from the Hospital Authority, and attracted interest from overseas buyers in Thailand, Indonesia, the Philippines and India, with potential orders ranging from US$10,000 to several hundred thousand dollars.

This year’s Medical Fair attracted a significant number of buyers from emerging markets seeking sourcing opportunities. Dr Keo Sovann, an otorhinolaryngologist from Orchid Hospital in Cambodia who visited the fair specifically for new medical equipment, said, “I met more than 10 exhibitors from Chinese Mainland, Australia and Malaysia, which has helped expanding our hospital’s procurement network and advanced our internationalization efforts. I am particularly interested in a Hong Kong company’s AI-powered medical imaging solutions and X-ray equipment; we are considering an order of 20 units.” A buyer from Morocco also attended the fair for the first time to source laboratory equipment. Rachid Zemmouri, Business Development Manager of Promamec, said he met with at least 15 exhibitors from Hong Kong, Chinese Mainland, Taiwan and Indonesia. Discussions are underway on thermodynamics-related solutions with the aim of application to eye-disease treatment. Subject to satisfactory progress, he plans to invite partners to Morocco for site visits. He added that the company has an annual procurement budget of approximately US$70 million and intends to return for future sourcing.

The Fair hosted over 50 themed forums and seminars, with leading technology companies, industry experts and academics sharing the latest industry trends, technological innovations and practical insights to foster in-depth exchange, collaboration and inspire trade buyers. Highlight sessions included “Accelerating Mental Health Innovation through AI Research and Adoption”, “HKMTA Medical Fair Forum 2026: The Medtech Solutions - Greater Bay Area & Overseas”, “The ASEAN Gateway: Navigating Regulations, Capital and Distributions from Hong Kong”, and “Decoding the Demand for Gerontechnology” among others, all of which attracted strong audience engagement. Selected sessions are available for replay on the Fair’s website for extended engagement.

The exhibition continued to adopt the EXHIBITION+ hybrid model. Global exhibitors, industry professionals, and buyers could make use of the Click2Match and explore sourcing opportunities via HKTDC Sourcing. Click2Match will remain available until 20 May.

Photo download: https://bit.ly/4nokRfT

Websites

International Healthcare Week: https://internationalhealthcareweek.hktdc.com/en

Asia Summit On Global Health: https://www.asiasummitglobalhealth.com/conference/asgh/en

Hong Kong International Medical and Healthcare Fair: 
https://www.hktdc.com/event/hkmedicalfair/en

List of Product: https://www.hktdc.com/event/hkmedicalfair/en/product  

Media enquiries

Yuan Tung Financial Relations:

HKTDC’s Communications & Public Affairs Department:

About HKTDC

The Hong Kong Trade Development Council (HKTDC) celebrates its 60th anniversary this year. The HKTDC is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in the Chinese Mainland, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. 

HONG KONG, May 13, 2026 - (ACN Newswire) - SinoMab BioScience Limited (“SinoMab” or the “Company”, together with its subsidiaries, the “Group”; stock code: 03681.HK) is pleased to announce that Dr. Shui On Leung, Executive Director, Chairman and Chief Executive Officer of the Company, was invited as a special guest to present at the 2026 LifeArc Translational Science Summit in London,UK. As one of the most influential global events in translational medicine, the summit brought together top scientists, practicing clinicians, industry leaders, policymakers and institutional investors from across the globe. During the event, Dr. Shui On Leung delivered a keynote speech, systematically outlining SinoMab’s R&D strategies for autoimmune diseases and the latest clinical progress of its core pipeline, while engaging in in-depth dialogues with international peers.

Hosted by LifeArc, a prestigious UK medical research charity, the annual summit is committed to bridging early-stage scientific research and real-world clinical application, with profound expertise and influence in addressing rare diseases and wide-ranging unmet medical needs. This year’s summit centered on how translational research can accelerate the entire journey from laboratory discoveries to patient access, by advancing novel treatment modalities, transforming clinical practice, shaping health policies and driving commercial innovation. Attendees held interdisciplinary discussions on cutting-edge areas including antibody drugs, gene therapy and cell therapy, exploring solutions to break through core bottlenecks in translational medicine and boost integrated development across industry, academia, research and clinical sectors. Dr. Shui On Leung’s invitation to this high-profile event marks high recognition from leading international authorities of SinoMab’s innovative efforts in immunotherapy.

In his keynote address, Dr. Shui On Leung analyzed the current landscape and prevailing challenges in global R&D for autoimmune disease therapeutics, and elaborated on SinoMab’s differentiated innovation framework anchored in “First-in-Class” and “Best-in-Class” drug development. He gave a detailed introduction to SM17, the Company’s flagship humanized monoclonal antibody targeting the interleukin-25 (IL-25) receptor. By precisely binding to IL-25 receptor, a key upstream alarmin molecule regulating type 2 immune responses, SM17 blocks inflammatory cascade reactions at the source. It holds broad therapeutic potential for a spectrum of inflammatory and immune-mediated disorders, including atopic dermatitis (AD), inflammatory bowel disease (IBD), asthma, chronic rhinosinusitis with nasal polyps, and idiopathic pulmonary fibrosis. Dr. Leung shared a series of landmark milestones achieved by SM17 recently. In the AD treatment landscape, Phase 1b clinical data demonstrated outstanding therapeutic efficacy. In the high-dose cohort, 91.7% of patients reported significant itch relief measured by the NRS-4 scale, 75% achieved EASI 75 skin lesion improvement, and 41.7% attained complete or near-complete clearance of AD symptoms (IGA 0/1). Such clinical outcomes outperform existing IL-4/IL-13 targeted monoclonal antibodies, while the product also boasts a more favorable safety profile compared with JAK inhibitors. Building on these promising results, the Phase II clinical trial of SM17 for moderate-to-severe AD completed first patient dosing in mainland China on 31 March 2026. The trial plans to enroll approximately 210 participants, with full enrollment expected in the second half of 2026 and topline clinical data slated for release in the first half of 2027. In terms of administration convenience, the Phase I bridging study of SM17 subcutaneous formulation released positive topline results on 25 March 2026. Data from 30 healthy volunteers confirmed the subcutaneous injection route with satisfactory safety and stable pharmacokinetic performance. Only one mild Grade 1 injection site rash was reported, which resolved spontaneously without intervention, and robust absolute bioavailability was validated, laying a solid foundation for the development of more user-friendly subcutaneous dosing regimens. Furthermore, SM17 has successfully expanded its therapeutic indications to IBD. Its Investigational New Drug (IND) application for Crohn’s disease and ulcerative colitis was officially approved by China’s National Medical Products Administration (NMPA) on 24 February 2026. Relevant bridging studies were finalized in the same month, paving the way for direct progression to Phase II clinical development. Dr. Leung also highlighted the Company’s innovative early-stage pipeline, including the anti-CGC antibody (a first-in-class humanized anti-γc antibody), which has demonstrated potential in the treatment of autoimmune diseases such as alopecia areata and vitiligo, with an IND submission planned for the fourth quarter of 2026. A novel bispecific antibody targeting RANKL and sclerostin has demonstrated superior efficacy over marketed therapies in preclinical studies for bone-related disorders, and its IND filing is targeted for the first half of 2027. Dr. Leung emphasized that by focusing on innovative and untapped drug targets, SinoMab has built a synergistic product portfolio, striving to deliver safer, more effective and more accessible breakthrough therapies for patients worldwide.

Being invited to this LifeArc Translational Science Summit is not only a strong recognition from a respected international institution of SinoMab’s innovative edge and exploratory work in antibody R&D, but also a key opportunity to deepen our global partnerships. Through in-depth exchanges with leading scientists, clinical researchers and senior executives of multinational pharmaceutical companies, SinoMab has further expanded its international academic network and potential partnership channels, laying a solid foundation for future technology in-licensing, co-development, out-licensing and commercialization. Dr. Shui On Leung stated that the Company will remains focused on addressing unmet clinical needs in autoimmune diseases. It will accelerate global multi-center clinical development of core pipeline assets such as SM17, while actively exploring how AI and other new technologies can boost novel target discovery. In addition, drawing on strategic collaborations with institutions like the Sun Yat-sen University Institute of Advanced Studies Hong Kong, SinoMab aims to strengthen its translational capabilities from bench to bedside. Looking ahead, SinoMab will seize the rapid growth opportunities in China’s biotech out-licensing market, stay true to a differentiated global innovation path, and actively pursue diversified collaboration models with global partners, and accelerate the delivery of innovative therapies to patients worldwide, while creating long-term value for shareholders.

About SinoMab BioScience Limited

SinoMab BioScience Limited (Stock Code: 03681.HK) is a pioneer in the research and development of first-in-class and potential best-in-class therapeutic antibody drugs, focusing on autoimmune diseases, neurodegenerative disorders, and other debilitating diseases, committed to addressing unmet medical needs. SinoMab has consistently focused on developing therapeutic antibodies targeting novel targets and employing innovative mechanisms, aiming to achieve differentiated clinical outcomes in areas where existing therapies have shown limited efficacy. Its rich R&D pipeline includes: SM17, which has demonstrated exceptional anti-pruritic effects, skin clearance rates, and safety profiles in the treatment of AD, with potential applications in asthma and idiopathic pulmonary fibrosis (IPF); its flagship anti-CD22 antibody, Suciraslimab , which has been clinically validated for efficacy in rheumatoid arthritis (RA) and is currently undergoing clinical evaluation for systemic lupus erythematosus (SLE) and Alzheimer's disease; another innovative anti-CGC (common gamma chain) monoclonal antibody, which is preparing to enter clinical studies for the treatment of alopecia areata and vitiligo; and a bispecific monoclonal antibody developed by SinoMab that simultaneously stimulates bone growth and inhibits bone loss for the treatment of osteoporosis. With breakthrough efficacy as its core pursuit, SinoMab continuously redefines patient care standards and maintains a leading position in the field of breakthrough therapies.  

This press release is issued by Zhenzhuo Group on behalf of SinoMab BioScience Limited.

Investor and Media Inquiries

Contact Person:
Bunny Lee
Nomia Zhou
Qiuyan Deng
Phone: (852) 5316 9995
Email: ir_sinomab@zhenzhuoglobal.com

HONG KONG, May 11, 2026 - (ACN Newswire) - The fifth International Healthcare Week (IHW), organised by the Hong Kong Trade Development Council (HKTDC), opens today, featuring two flagship events. The sixth Asia Summit on Global Health (ASGH) is being held today and tomorrow (11 and 12 May) at the Hong Kong Convention and Exhibition Centre (HKCEC) under the theme “Fuelling Healthcare Breakthroughs”. The summit convenes over 90 influential international healthcare officials, research and medical experts, start-ups, investors, and business leaders from related industries to explore global healthcare trends, with a focus on frontier technologies, AI breakthroughs, pandemic preparedness, silver health, as well as innovation in Chinese medicine, in alignment with the National 15th Five-Year Plan. Another flagship event, the 17th Hong Kong International Medical and Healthcare Fair (Medical Fair), also opens today (11 to 13 May) under the theme “Innovations Boosting Smart Health Experience”, featuring some 300 exhibitors from 10 countries and regions. The Fair spotlights MedTech, GeronTech and Preventive Healthcare, showcasing the latest medical innovations integrating artificial intelligence and robotics, fostering global exchange in healthcare innovation and reinforcing Hong Kong’s strengths as a research and commercial hub.

Prof Frederick Ma, Chairman of the HKTDC, said in his welcome remarks: “There is nowhere better than Hong Kong, as a major international hub for financing and innovation, to explore areas of global collaboration in the health arena, and to showcase related business opportunities for investors and project owners. As a superconnector and super value-adder, Hong Kong has a long track record of helping companies and innovations break through. The theme we have adopted this year, ‘Fuelling Healthcare Breakthroughs’, highlights this vital role. The ASGH was created to nurture partnerships and knowledge exchange that can drive real change and create a better world. This year’s agenda also complements the healthcare priorities set out in China’s new 15th Five-Year Plan, supporting national development. Among the diverse topics at ASGH 2026 are sessions examining AI-enabled diagnosis and treatment, biomedical innovation, the growth of the silver health economy, traditional Chinese medicine and much more.”

John Lee, Chief Executive of the HKSAR, said in his opening remarks: “Hong Kong, under the ‘one country, two systems’ principle, is investing in healthcare and, in doing so, investing in the future of our people and our economy. Our status as a leading hub for scientific innovation is unrivalled in Asia. And our strengths are magnified by our core position in the Guangdong-Hong Kong-Macao Greater Bay Area. That is the cluster city development integrating 11 dynamic cities in southern China. It boasts a collective economy that rivals that of the world's 10th-largest nation. In pursuit of medical innovation, Hong Kong complements the strategies set out in the National 15th Five-Year Plan. The Plan optimises an evaluation and approval mechanism for innovative drugs and supports their clinical application. The goal is to develop Hong Kong into a health and medical innovation hub. Central to this ambition is the rapid expansion of our clinical trial capabilities, the vital engine that drives biomedical R&D from the laboratory to the bedside.”

Prof Zeng Yixin, Vice Minister of the National Health Commission of the People’s Republic of China, delivered special remarks: “Hong Kong has extensive experience in undergraduate medical education and post-graduate training, and enjoys a strong reputation in the Asia-Pacific region. Medical talent training system on the mainland is also undergoing deep reforms and striving to move towards high-quality development. Hong Kong has many experiences and practices that are worthy of in-depth exchange and reference, which will certainly promote mutual enhancement and progress.”

Global leaders convene to explore collaboration opportunities

This morning’s Plenary Session I: Strengthening Pandemic Preparedness through Global Collaboration, featured keynote speech by Prof Lo Chung-mau, Secretary for Health of the HKSAR government, who said: “Hong Kong has long been recognised for the quality and efficiency of our healthcare system. We consistently rank at the top of global health indices, with a life expectancy that remains among the highest in the world, with women over 88 years and men about 83 years in 2024. Our public healthcare system serves as a robust safety net, ensuring universal health coverage for all at a very low cost. The National 15th Five-Year Plan calls for a health-first development strategy. Hong Kong is fully aligned and will continue to contribute to this national vision through our work in pandemic preparedness and medical innovation.”

Prof Leo Poon, Daniel C K Yu Professor in Virology at the School of Public Health of the University of Hong Kong and Co-Director of the Hong Kong Jockey Club Global Health Institute, moderated the session. Distinguished speakers included Prof Ibrahim Abubakar, Vice-Provost (Health) and Professor of Infectious Disease Epidemiology at University College London; Feng Lan, Vice President, China Pharmaceutical Innovation and Research Development Association; Dr Leung Yiu-hong, Head of Emergency Response and Programme Management Branch, Department of Health of the HKSAR government; Dr Kumanan Rasanathan, Executive Director of the WHO Alliance for Health Policy and Systems Research; Prof Wang Yu, Chairman of the Chinese Foundation for Hepatitis Prevention and Control, also Former Director-General, Chinese Centre for Disease Control and Prevention; and Dr In-Kyu Yoon, Deputy Director General for Integrated Development and Pandemic Preparedness at the International Vaccine Institute. They discussed key strategies to strengthen the resilience of the global health system in response to future pandemics. Dr Kumanan Rasanathan said: “Public health agencies need to maintain scientific independence to synthesize, act upon, and provide advice based on the best available science. They also require operational flexibility because, during a pandemic or outbreak, it is not sufficient to rely solely on strategies used for previous outbreaks.”

Plenary Session II: Fuelling Healthcare Breakthroughs was moderated by Victor Chu, Chairman and CEO of First Eastern Investment Group. Speakers included Clara Chan, CEO of Hong Kong Investment Corporation Limited; David Lau, Vice Chair of Investment Banking for Asia Pacific and Head of Healthcare Investment Banking for Asia Pacific at JP Morgan Securities; Dr Inna Menkova, Chief Executive Officer, Allogenica; Jonathan Symonds, Chairman of the Board of GSK; and Theresa Tse, Chairwoman of the Board, Sino Biopharmaceutical Limited; They examined investment trends and market transformation in biopharmaceuticals and explored how cross-sector collaboration can drive healthcare breakthroughs.

One of the highlights this afternoon, the Dialogue with Global Pioneer in Health session, featured 2013 Nobel Prize laureate in Chemistry, Prof Michael Levitt, Robert W and Vivian K Cahill Professor in Cancer Research at Stanford University. He shared insights into his research and the future of technology-driven healthcare innovation, exploring how biological intelligence is shaping the future of healthcare. He said: “One of the secrets of successful evolution is to be as diverse as possible. This diversity then leads to intelligence.”

Thematic sessions spotlight cutting-edge healthcare innovation and AI applications

As the global healthcare industry accelerates towards technology-driven transformation and industrial upgrading, multiple thematic sessions at the summit focus on the application of innovative technologies across the sector. Topics include AI-enabled healthcare, medical robotics and devices, cell and gene therapies, biomedical, and the silver economy, showcasing the latest market trends and aligning with the National 15th Five-Year Plan to advance the development of a “Healthy China” and foster AI and healthcare innovation. The first day featured a dedicated session, The Next Frontier in China's Healthcare Industry, moderated by Nisa Leung, Managing Partner of Aulis Capital, with speakers including Mark Gavin Lotter, Founder and CEO of Nuance Pharma; Wu Hao, Executive Director and Co-President of Tigermed; and Seth Zhang, Founder and CEO of MediTrust Health. They discussed strategies to drive the development of the Chinese Mainland healthcare sector. Wu Hao said: “By giving China-led industry data and applications greater exposure and participation on the global stage, Chinese enterprises can take a seat at the table and become true leaders.”

Several thematic sessions spotlight the large-scale application of AI in healthcare. These include this afternoon’s sessions: Intelligence at Scale: How AI is Powering Real-World Healthcare Revolution, moderated by Dr Kenneth Tsang, Regional Chief Executive Officer of IHH Healthcare North Asia and CEO of Gleneagles Hospital Hong Kong, featured speakers including Prof Joshua Ho, Assistant Dean (Innovation and Technology Transfer) in the Li Ka Shing Faculty of Medicine at the University of Hong Kong; and Reshaping Tomorrow’s Healthcare: Advances in Medical Robotics and Devices, further explored the transformative role of AI in medical robotics and next-generation medical devices, showcasing cutting-edge innovations and breakthrough developments. Tomorrow afternoon’s session, Transforming Healthcare through Digital Health & AI Innovations, with speakers from Healthtech Finland, Heidi Health, Pfizer, The Hong Kong Polytechnic University and other leading organisations, will offer multi-dimensional insight into AI applications and breakthroughs in the healthcare field.

A new session this year, CSO Insights: Catalysing Scientific Breakthroughs and Investments for Future Health, will bring together leading scientists from global pharmaceutical companies, including Dr Li Xiang, Senior Vice President, Co-President and Chief Scientific Officer of Innovative Medicines Division at Fosun Pharma, to discuss transforming research breakthroughs into real-world healthcare applications.

Building on last year’s Silver Health Chapter, tomorrow will feature the session Unlocking Growth in Silver Health: From Precision Medicine to Smart Ageing Innovations. Speakers include Prof Christopher Chao, Vice President (Research and Innovation) of the Hong Kong Polytechnic University; Prof Brian Kennedy, Director of the Centre for Healthy Longevity at the National University Health System, Singapore; and Zhang Junjie, Vice President of Ant Group and President of Healthcare Business Group. They will share insights into ageing-related disease prevention and solutions.

Other sessions also cover a wide range of cutting-edge topics, including Driving Chinese Medicine Development Through Standardisation and Innovation, and IP Financing and Trading for Pharmaceutical and Health Technology. These thematic sessions examine the latest developments and trends in the healthcare industry from multiple perspectives, promoting exchanges among scientific research, market applications and industry policy. During the session From Detection to Cure: Accelerating Innovations for Rare Diseases, Prof Liang Zicai, Founder and Chairman of Suzhou Ribo Life Science, will explore how innovative diagnostics and treatments are bringing new hope to patients. Another session, Charting the Future: A New Era in Gene and Cell Therapies, brought together Dr Li Xiang, Founder and CEO of XellSmart, and Dr Zhu Tian, Co-founder and CEO of GenEditBio, who shared the latest advancements in stem cell biology and genome editing platforms with other guests.    

A global platform for healthcare resource matching, empowering pharmaceutical and healthcare companies to expand their business

In addition to symposium sessions, some 180 healthtech companies from 12 countries and regions are showcasing innovative projects and solutions at the ASGH Business Hub and InnoHealth Showcase. At the same time, Project Pitching provides start-ups with opportunities to connect with investors, while the ASGH Deal-making facilitate one-on-one meetings to match global capital with healthcare projects. Participants can also access professional advice at the “GoGlobal Connect” and Business of Healthcare Advisory Zone, enabling companies to develop more targeted strategies for business expansion.

Medical Fair showcases diverse AI-driven health solutions, with smart ageing products surge twofold

The 17th Hong Kong International Medical and Healthcare Fair, organised by the HKTDC and co-organised by the Hong Kong MedTech Association, opened alongside ASGH. With the theme Innovations Boosting Smart Health Experience, the Fair brings together some 300 exhibitors from 10 countries and regions, including Hong Kong, the Chinese Mainland, Taiwan, Korea, as well as new participants from Macao, Australia, Canada, New Zealand, Vietnam and the United States, highlighting Hong Kong’s strengths as an international medical innovation hub.

The Fair focuses on three key areas: MedTech, GeronTech and Preventive Healthcare, presenting a comprehensive showcase of the latest medical and healthcare equipment, products and application solutions from around the world. For MedTech, Neuroptek Corporation Inc from Canadian pavilion (Booth No.: 3E-D16) showcases the brand new EyeMirage, a solution that extends professional ophthalmic vision examinations beyond the clinic. By leveraging the computing power and camera technology of smartphones, the system enables users to conduct high-quality vision tests in settings such as homes and schools. Meanwhile, HKG epiTherapeutics Limited (Booth number: 3E-E06), from the Hong Kong Science and Technology Parks, presents a DNA methylation analysis technology designed for the early screening of liver cancer. The solution can identify and distinguish differential methylation features among liver cancer, blood and normal tissues. Its clinical research findings have been published in leading international academic journals[1], demonstrating a sensitivity of 88.5% for early-stage liver cancer and 95.7% for late-stage cases, representing one of the highest performance levels globally in methylation-based liver cancer early screening.

In the field of GeronTech, the exhibits span a wide range of products, including smart rehabilitation robots, AI-powered mental health assessment systems, smart elderly care solutions and home-based care devices, fully addressing the evolving market needs of the silver economy. Hanshin Technology Limited (Booth No.: 3E-D13) introduces a Smart Shower Robot, which enhances safety and comfort for the elderly during bathing through intelligent design, while also easing caregivers’ workload and supporting the practical adoption of smart care solutions. Notably, the number of smart ageing products exhibited this year has more than doubled compared with the last edition, underscoring strong and growing market demand.

In Preventive Healthcare, an exhibitor from Chinese Mainland, Guangzhou Supbio Bio-Technology and Science Co., Ltd. (Booth No: 3E-E19), presents the world’s first HIV-1 DNA quantitative testing kit approved for market launch by the National Medical Products Administration (NMPA). Designed to address increasingly complex HIV testing needs, the solution provides a stable and reliable full-disease-course testing approach, supporting an integrated and innovative model that spans prevention, treatment efficacy assessment and the exploration of functional cure through precision diagnostics.

The Medical Fair features more than 50 themed forums and seminars, including topics such as “HKMTA Medical Fair Forum 2026: The Medtech Solutions - Greater Bay Area & Overseas”, co-organised with the Hong Kong MedTech Association, to be held tomorrow morning (12 May), followed by the afternoon session “ASEAN Gateway: Navigating Regulations, Capital and Distributions from Hong Kong”. On Wednesday (13 May), sessions such as “Decoding the Demand for Gerontechnology” will also take place. Industry experts will share the latest insights and market trends, and the exhibition will provide an ideal platform for professionals to network and explore new business opportunities. 

The exhibition will continue to adopt the “EXHIBITION+” hybrid model. The physical fair will take place from 11 to 13 May at the HKCEC. Global exhibitors, industry professionals, and buyers can engage in discussions via the “Click2Match” smart business matching platform from 4 May until 20 May.

Photo download: https://bit.ly/4tsy9Js

Websites

International Healthcare Week: https://internationalhealthcareweek.hktdc.com/en

The Asia Summit on Global Health: https://www.asiasummitglobalhealth.com/conference/asgh/en?ref_source=GrayMenu&ref_medium=vep-conference

Hong Kong International Medical and Healthcare Fair: https://www.hktdc.com/event/hkmedicalfair/en?ref_source=GrayMenu&ref_medium=vep-tradeshow

List of Product: https://www.hktdc.com/event/hkmedicalfair/en/product?ref_source=GrayMenu&ref_medium=vep-tradeshow

Media enquiries

Yuan Tung Financial Relations:

Jasmine Zhang      Tel: (852) 3428 3278   Email: jzhang@yuantung.com.hk

Louise Song        Tel: (852) 3428 5691   Email: lsong@yuantung.com.hk

Tiffany Leung      Tel: (852) 3428 2361   Email: tleung@yuantung.com.hk

HKTDC’s Communications & Public Affairs Department:

Noah Qiu           Tel (852) 2584 4575    Email: noah.yl.qiu@hktdc.org

Navin Law          Tel: (852) 2584 4525   Email: navin.cm.law@hktdc.org

Jane Cheung        Tel: (852) 2584 4137   Email: jane.mh.cheung@hktdc.org

About HKTDC

The Hong Kong Trade Development Council (HKTDC) celebrates its 60th anniversary this year. The HKTDC is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in the Chinese Mainland, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. 

[1] The product was published in the world-leading academic journal Nature Communications (2023).

PHILADELPHIA, PA, May 8, 2026 - (ACN Newswire) - TruMerit, a global leader in healthcare workforce development and credential verification, today announced that it has issued its first verifiable digital credentials to healthcare professionals through a new partnership with Credivera, marking a major step forward in secure, portable credential verification for the global healthcare workforce.

The first group of digital credentials has been awarded to nurses and other healthcare professionals who successfully passed TruMerit's global certification examinations over the last year. These include the Certified Global Nurse credential and credentials tailored for nurses and other healthcare workers specializing in rehabilitation care. These secure credentials can now be stored, managed, and shared digitally, allowing employers, regulators, and licensing authorities to instantly verify professional qualifications.

Through Credivera's secure credential exchange platform, TruMerit credentials are issued in encrypted, tamper-proof digital formats that align with globally recognized verification standards. As healthcare systems worldwide face workforce shortages and increasing cross-border mobility of healthcare professionals, trusted credential verification has become a critical infrastructure challenge for regulators, employers, and governments. Verifiable digital credentials enable professional qualifications to be securely issued, instantly validated, and easily shared across borders--reducing administrative delays while strengthening confidence in the authenticity of healthcare credentials.

"By introducing verifiable digital credentials with Credivera--and issuing the first credentials to successful certification candidates--we are helping build a trusted digital identity for healthcare professionals that allows their qualifications to be securely verified anywhere in the world," said Peter Preziosi, President and CEO of TruMerit. "This initiative modernizes credential verification and gives professionals greater control over how their achievements are shared with employers and regulators."

Credivera supports a growing global network of organizations issuing encrypted credentials and verified identity records through its secure credential exchange infrastructure.

"Professional credentials are increasingly becoming part of a person's digital identity," said Dan Giurescu, CEO of Credivera. "Our platform allows trusted organizations like TruMerit to issue secure, verifiable credentials that professionals can control and share anywhere in the world. Together we are helping create a more transparent and trusted system for verifying healthcare qualifications."

The TruMerit-Credivera collaboration represents part of a broader shift toward verifiable digital identity systems, where trusted organizations issue portable credentials that professionals can carry throughout their careers.

About TruMerit

TruMerit is a worldwide leader in healthcare workforce development with nearly 50 years of experience supporting the mobility of nurses and other healthcare workers. Formerly CGFNS International, TruMerit validates the education, training, and professional experience of internationally educated health professionals seeking authorization to practice in the United States and other countries. Through its expanded mission and the Global Health Workforce Development Institute, TruMerit advances research, standards, and certifications that strengthen the global health workforce and promote equitable, sustainable career mobility. www.trumerit.org.

Media Contact:
LEA SIMS
Chief Marketing & Communications Officer
TruMerit
media@trumerit.org

SOURCE: TruMerit

ANTWERPEN, BELGIUM, May 7, 2026 - (ACN Newswire) - OMP, a leader in AI-powered supply chain planning, brings AstraZeneca to the Gartner Supply Chain Symposium/Xpo™ 2026 in Barcelona. Together, they will share how AstraZeneca is transforming planning to keep pace with increasing complexity and constant change - building an integrated, decision-centric approach powered by OMP's Unison Planning™ platform and UnisonIQ AI orchestration.

AstraZeneca's journey to decision-centric planning

Diane Gorman, Network Supply Planner at AstraZeneca, takes the Gartner stage to share how the global biopharmaceutical company is evolving from spreadsheet-based planning to integrated, capacity-aware decision-making. The session covers how this shift improves visibility into constraints and strengthens outcomes across campaign management, capacity planning, and detailed scheduling.

Gorman will address:

• What it takes to drive user adoption across a complex organization
• How planner roles evolve as planning becomes more system-supported
• How AstraZeneca is preparing for the next phase of AI-enabled decision support

Sign up for the session

OMP hosts theater session on decision velocity in practice

OMP will also host a theater panel on Tuesday, May 19, 5:25-5:45 PM featuring Jack Eggels, former VP of Supply Chain at Shell, Tom Wouters, Chief Product Officer at OMP, and Philip Vervloesem, OMP's Chief Commercial & Markets Officer.

Together, they explore:

• How organizations shift from calendar-driven planning to always-on, event-driven intelligence
• How decision velocity becomes a real operational capability with UnisonIQ coordinating human and AI collaboration
• How AstraZeneca's journey connects product innovation to measurable results across industries.

Explore decision velocity at the OMP booth

Throughout the Gartner Supply Chain Symposium/Xpo™ (May 18-20, Barcelona), OMP is present at booth 310, demonstrating how Unison Planning™ and UnisonIQ help organizations move toward always-on supply chain orchestration. See how integrated planning, enhanced by the latest AI advancements, drives faster scenario evaluation, stronger collaboration, and measurable business results.

Join OMP at Gartner to hear AstraZeneca's journey firsthand and leave with a clearer path to faster, more confident decisions.

Book a meeting on site

Session at a glance

• Title: AstraZeneca's Journey to Decision-Centric Autonomous Planning
• Speaker: Diane Gorman, Network Supply Planner, AstraZeneca
• When: Monday, May 18, 11:45 - 12:15 CEST
• Where: International Barcelona Convention Center

To see where you can meet OMP next, visit our events calendar here.

About OMP

OMP helps companies facing complex planning challenges to excel, grow, and thrive by offering the best digitized supply chain planning solution on the market. Hundreds of customers in a wide range of industries - spanning consumer goods, life sciences, chemicals, metals, paper, packaging, plastics, tires, and building products - benefit from using OMP's unique Unison Planning™.

Solution and product inquiries

Contact OMP
+32 3 650 22 11

Media inquiries
Kira Perdue (Carabiner)

SOURCE: OMP

Against this backdrop, Sichuan Neautus Traditional Chinese Medicine (Pieces) Co., Ltd. (“Neautus”) has completed its filing with the China Securities Regulatory Commission (CSRC) for overseas issuance and submitted its listing application to the Hong Kong Stock Exchange on April 30, 2026. The development marks a meaningful step in bringing a traditionally fragmented industry closer to capital markets, with increasing investor focus on sustainable growth, operational discipline, and cash flow quality.

Scale and Standardization Position Leaders to Benefit

Despite its large market size, estimated at around RMB 300 billion, the TCM decoction pieces industry remains relatively fragmented, leaving substantial room for consolidation. As regulatory standards continue to improve and healthcare procurement systems become more structured, competition is increasingly centered on supply chain capability, production standardization, quality control, and distribution efficiency.

In this environment, companies with established scale and standardized production systems are well positioned to benefit from ongoing industry upgrades. As standardization deepens and regulatory oversight strengthens, these advantages are expected to translate into gradual and sustained market share gains.

Sustained Growth with Strengthening Profitability

Neautus has delivered sustained revenue growth in recent years, with revenue increasing from RMB 1.146 billion in 2023 to RMB 1.335 billion in 2025.

Profitability has also improved alongside revenue expansion. Net profit for 2025 reached approximately RMB 106 million, while adjusted net profit, excluding listing-related expenses, rose to around RMB 127 million.

In the TCM decoction pieces sector, margins are generally stable rather than high, with profitability primarily driven by scale efficiency, cost control, and operational execution. Neautus’ performance reflects effective expansion under this model, supporting more sustainable and consistent profit growth while maintaining a well-balanced alignment with the needs of the healthcare system and ensuring stable and reliable supply to medical institutions.

Cash Flow Improvement Reinforces Earnings Quality

The company’s operating cash flow has improved significantly, rising from RMB 74.85 million in 2023 to RMB 154 million in 2025.

This trend highlights strengthening cash generation and improving earnings quality. The ability to translate revenue growth into operating cash flow is a key indicator of operational efficiency and financial discipline, and provides a solid foundation for future expansion.

Enhanced cash flow also supports greater financial flexibility, enabling the company to invest in capacity, quality systems, and channel development while maintaining balance sheet stability.

Disciplined Financial Structure Supports Sustainable Growth

Neautus maintains a balanced and disciplined financial structure. Accounts receivable have grown broadly in line with revenue and remain predominantly short-term in nature, with minimal long-aging exposure, indicating strong collection capability and customer quality.

At the same time, payables have remained stable, suggesting that the company has not relied on extending supplier credit to support growth. This reflects a measured and sustainable approach to working capital management.

Leverage levels have also improved, with the gearing ratio declining to 47% in 2025. Overall, the company’s financial profile demonstrates prudent risk management while supporting continued business expansion.

Cost Management Capability Enhances Resilience

In recent years, elevated raw material prices have increased cost pressure across the TCM decoction pieces industry, placing greater emphasis on procurement capability and operational efficiency.

Companies with stronger scale advantages are typically better positioned to manage such volatility, benefiting from improved bargaining power and cost control. Neautus’ ability to sustain growth during periods of higher input costs reflects operational resilience and effective cost management.

As raw material prices gradually stabilize, the industry may enter a phase of margin recovery, with companies that have established scale and efficiency advantages potentially seeing further improvement in profitability.

Leadership and Strategic Positioning

Neautus’ management team combines deep industry experience with technical expertise. Founder Jiang Yun has extensive experience in the pharmaceutical sector and was an early participant in advancing GMP-based production systems for TCM decoction pieces.

He has also been actively involved in industry standard-setting, including serving on the 10th Chinese Pharmacopoeia Committee. His contribution to the development of a DNA-based identification system for Chinese medicinal materials, now incorporated into the Chinese Pharmacopoeia, reflects a long-term focus on standardization and quality control.

At the management level, Jiang Ercheng, with a biochemistry background from the University of California, Los Angeles and Hong Kong Baptist University, is involved in research and strategic initiatives.

This combination of operational depth and standardization expertise may support the company’s strategic positioning as the industry continues to consolidate and move toward higher regulatory and quality standards.

Capital Market Progress Signals Industry Momentum

The TCM decoction pieces sector is supported by stable demand fundamentals, significant market size, and increasing regulatory standardization. At the same time, relatively low industry concentration continues to provide room for leading enterprises to expand.

In this context, Neautus’ listing progression represents not only an important corporate milestone but also a broader signal of the sector’s accelerating integration with capital markets.

Looking ahead, the company appears to be building a balanced development profile across growth, profitability, and cash flow. As industry consolidation advances and standardization deepens, companies with scale, operational discipline, and financial strength are expected to play an increasingly prominent role, with long-term value gradually becoming more visible to the market.

The centerpiece is HEAL-Healthy Eating & Active Living, ideally whole‑food plant‑predominant/vegetarian-vegan diets & daily exercise outdoors/active mobility-as the minimum, first‑line standard in health and care. The authors urge immediate action on Prevention-over-Treatment and reforming education and human‑relevant science (drug failure rate from animal studies is 90-95%, and as high as 99.6% for Alzheimer disease), with a rapid shift from disease‑centered reaction to person‑centered, lifestyle‑first cure and care.

Figure 1. HEAL means choosing a whole-food, plant-predominant (ideally vegan) diets coupled with daily exercise outdoors/in nature to kick-start better health. Credit: iStock/LightFieldStudios.

"Sustainable health is for free but cannot be downloaded or prescribed-it must be lived daily and earned across lifetime through informed lifestyle choices, with HEAL as starting point. As childhood-entrenched health literacy lasts a lifetime; embedding HEAL from primary to tertiary education is the policy priority of our generation." -Lead author Katharina Wirnitzer | PHT, University of Innsbruck & CCCTIM

Figure 2. Katharina Wirnitzer/Keynote on Vegan Diet in Sports. Credit: ©Katharina Wirnitzer.

Why change is imperative

• The paradox: Despite rising health spending and scientific advances, public health gains lag while ever-growing NCDs. The expert panel offers 101 consensus statements and a 10‑step policy roadmap to act across the lifespan-from individual behavior to population‑level change.
• Why HEAL, and why now: HEAL combines Healthy Eating (whole‑food, plant‑predominant; preferably vegetarian/vegan) with Active Living (regular, ideally daily, including outdoor activity and active mobility). Evidence shows synergistic benefits beyond either alone, reducing reliance on drugs and surgery while improving resilience and sustainability of health systems.
• Prevention-First (3:1): The reports recommend prioritizing prevention, health maintenance, and health promotion over treatment by 3:1 (Figure 3), making healthy choices the easy, first‑line intervention and reserving medicalized treatment for specific indications.
• Education and workforce: Embed HEAL from primary through tertiary education and continuously upskill healthcare and education professionals to deliver evidence‑based lifestyle counseling, routine assessment, and monitoring. Improve meal standards and support active mobility in schools and public spaces.
• Human‑relevant science: Accelerate the transition to non‑animal, human‑relevant methods for basic and preclinical research and for efficacy, safety and toxicity testing through funding priorities, validation, and regulatory adoption.
• Policy roadmap: Apply Health in All Policies (HiAP) to link individual choices with systemic supports (Figure 4); invest in supportive defaults (healthy public catering, active transport, public‑space design, community HEAL programs); embed HEAL in curricula; and track outcomes with robust evaluation to scale what works.

"Every dollar/euro invested in evidence-based prevention saves multiples in treatment. HEAL is the smartest first investment a health system can make." -Bernd Haditsch | ÖGK - Austrian Health Insurance Fund, Prevention Unit

"Obesity is a disease with powerful drivers. HEAL gives every patient a proven, first-line foundation to reclaim their health." -Fatima Cody Stanford | Harvard Medical School & MGH

"A doctor who cannot counsel patients on the Power of Lifestyle, especially on food and movement, is only half-equipped. Lifestyle education in medical school is the missing foundation of modern medicine. Helping our patients to eat a more plant-strong diet is the most powerful healing medicine we can prescribe." -Michael Klaper | Moving Medicine Forward

"Plant-forward diets provide a powerful opportunity to concurrently improve health and wellbeing for people, farmed animals and the environment." -Andrew Knight | Griffith University

Figure 3. Four areas-of-action, balanced 3:1, to achieve lifelong health. Credit: ©Katharina Wirnitzer.

"Given its cost-effectiveness, Traditional, Integrative, and Complementary Medicine will be the evidence-based mainstream of tomorrow's global healthcare." -Tomáš Pfeiffer | ITCIM & SANATOR

"Treatment alone will not sustain health systems. HEAL connects prevention, lifestyle medicine and integrative care to advance salutogenesis on a planetary scale. We must invest far more in creating health." -Georg Seifert | WHO CC & CCCTIM, Charité Universitäts mediz in Berlin

"The science clearly shows that, when it comes to human health, animal protection is a win-win. Given human health's complexity, and since animal testing virtually fails to cure human diseases, human-relevant methods already outperform animal experimentation and must therefore be implemented with priority in science, with funds going to human-focused research. Citizens in the EU and US have spoken clearly in favor of this transition. HEAL can prevent many diseases, avoiding the need for animal studies altogether." -Merel Ritskes-Hoitinga | Universities Aarhus & Utrecht; Doris Wilflingseder | Vetmed Uni Vienna, Aysha Akhtar | Center for Contemporary Sciences, Corina Gericke & Gaby Neumann | Doctors Against Animal Experiments

Figure 4. Systemic application of HEAL to reach target groups and improve personal and public health across micro (individuals/families), meso (communities), and macro (state/government/federal policy) levels, ensuring optimal vertical and horizontal permeability and integration. Credit: ©Katharina Wirnitzer.

Key Actions at a Glance.

• Make HEAL the universal starting point and minimum, first‑line prevention standard.
• Implement lifestyle‑first counseling before routine prescriptions.
• Prioritize Prevention-over-Treatment with an 3:1 balance.
• Mandate lifestyle education in schools; embed HEAL across tertiary programs.
• Continuously upskill professionals for evidence‑based lifestyle counseling and monitoring.
• Accelerate adoption of human‑relevant methods to end animal experiments in research, education and regulatory testing.

Figure 5. The Power of Lifestyle: Start with the dual HEAL approach across 6 interconnected areas to improve health and well-being. Credit: ©ACLM. Graphic modification: ©Katharina Wirnitzer (permission: 24.11.2021).

Contact for further information:
Katharina C. Wirnitzer - Professor for Sports Public Health with a special focus on Child Public Health
Email: katharina@wirnitzer.at
Cell: +43 (650) 5901794
University College of Teacher Education Tyrol (PHT), Innsbruck, Austria

SOURCE: Institut für Sekundarpädagogik

Related Documents:
global-pr-engmedia-prfinal28april2026
global-pr-engmedia-prfinal28april2026